We conducted a study to examine how certain serum metabolic markers (reactive oxygen species (ROS), homocysteine (Hcy), and reduced glutathione (GSH)) impact the levels of IL-4 in patients with insomnia. The study involved 60 insomnia patients, including 20 with primary insomnia and 20 with somatopathy insomnia, aged 23-84 years with a mean age of 61.20 ± 12.59 years and a mean disease duration of 6.97 ± 8.45 years. There were 20 normal controls, 11 males and 9 females, aged 26-63 years, with an average age of 49.95 ± 10.52 years. We measured ROS levels using immunofluorescence, Hcy levels using enzyme-linked immunosorbent assay, and GSH levels using ELISA. The IL-4 level in serum was also detected by ELISA to assess the patient's immune function. Our analysis revealed that changes in ROS, Hcy, and GSH levels were associated with changes in IL-4 levels in serum. Therefore, early detection of serum metabolic changes in insomnia patients and proactive intervention can help reduce susceptibility to various infections and tumors.